reasons why there are fewer treatment options for mds patients and hope for the future
Published 2 years ago • 53 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:02
emerging treatment options for lower- and higher-risk mds and ongoing trials
-
2:16
current and future treatment approaches for hr-mds
-
3:31
promising treatment options emerging for higher-risk mds & the value of clinical trials
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
4:28
understanding myelodysplastic syndromes (mds)
-
6:36
mds: low-risk disease treatment options
-
14:08
low-risk and high-risk mds
-
2:04
state-of-the-art treatment for hr-mds
-
1:30
the prognostic value of patient-reported outcomes in mds
-
22:26
what's your approach? treating myelofibrosis
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
3:08
the treatment protocol for higher risk mds
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
3:21
an insight into the standard of care in hr-mds and future outlooks
-
2:06
outcomes & promising treatment options following hma failure in patients with hr-mds
-
3:24
novel agents in higher-risk mds
-
2:21
targeted therapy for mds
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
6:01
treatment of myelodysplastic syndromes (mds)
-
1:00
how genomic testing has influenced treatment approaches and clinical trial design in mpns